Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Receivables (2016 - 2025)

Collegium Pharmaceutical has reported Change in Receivables over the past 10 years, most recently at -$22.6 million for Q4 2025.

  • Quarterly results put Change in Receivables at -$22.6 million for Q4 2025, down 21240.57% from a year ago — trailing twelve months through Dec 2025 was -$17.2 million (down 489.76% YoY), and the annual figure for FY2025 was -$17.2 million, down 489.76%.
  • Change in Receivables for Q4 2025 was -$22.6 million at Collegium Pharmaceutical, down from $20.9 million in the prior quarter.
  • Over the last five years, Change in Receivables for COLL hit a ceiling of $58.9 million in Q3 2021 and a floor of -$43.2 million in Q4 2021.
  • Median Change in Receivables over the past 5 years was -$1.1 million (2022), compared with a mean of $1.4 million.
  • Peak annual rise in Change in Receivables hit 10913.68% in 2025, while the deepest fall reached 21240.57% in 2025.
  • Collegium Pharmaceutical's Change in Receivables stood at -$43.2 million in 2021, then soared by 71.54% to -$12.3 million in 2022, then surged by 81.06% to -$2.3 million in 2023, then skyrocketed by 95.44% to -$106000.0 in 2024, then plummeted by 21240.57% to -$22.6 million in 2025.
  • The last three reported values for Change in Receivables were -$22.6 million (Q4 2025), $20.9 million (Q3 2025), and -$15.7 million (Q2 2025) per Business Quant data.